scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1032228410 |
P356 | DOI | 10.1186/1471-2407-6-123 |
P932 | PMC publication ID | 1475876 |
P698 | PubMed publication ID | 16681853 |
P5875 | ResearchGate publication ID | 7099003 |
P50 | author | Thomas Gruenberger | Q64836048 |
P2093 | author name string | B Schuell | |
W Scheithauer | |||
F Wrba | |||
Ch Zielinski | |||
P2860 | cites work | Amplification and overexpression of epidermal growth factor receptor gene in human oropharyngeal cancer | Q67484299 |
Association of epidermal growth factor-related peptides and type I receptor tyrosine kinase receptors with prognosis of human colorectal carcinomas | Q70792686 | ||
Classification of colorectal carcinomas with regional lymphatic metastases | Q71089424 | ||
Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung | Q72079143 | ||
Immunohistochemical p53 overexpression correlated to c-erbB-2 and cathepsin D proteins in colorectal cancer | Q73093342 | ||
The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer | Q73212054 | ||
HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors | Q75209089 | ||
Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival | Q77432075 | ||
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. | Q27824811 | ||
Cell signaling by receptor tyrosine kinases | Q27860474 | ||
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 | ||
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer | Q29617440 | ||
The ErbB/HER family of receptor tyrosine kinases: A potential target for chemoprevention of epithelial neoplasms | Q33890108 | ||
The HER-2/neu oncogene in tumors of the gastrointestinal tract | Q34311106 | ||
Staging of cancer of the colon and rectum | Q35758532 | ||
c-erbB-2 is not a major factor in the development of colorectal cancer | Q36644043 | ||
Receptor blockade with monoclonal antibodies as anti-cancer therapy | Q40585866 | ||
The epidermal growth factor receptor as a target for therapy in breast carcinoma | Q40665426 | ||
Cancer statistics, 1999. | Q40817780 | ||
Prognostic significance of p53 and c-erbB-2 immunohistochemical evaluation in colorectal adenocarcinoma | Q40981286 | ||
Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer | Q41756399 | ||
Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth | Q43619428 | ||
Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial | Q45217739 | ||
HER 2/neu expression and gene amplification in colon cancer | Q47887121 | ||
P407 | language of work or name | English | Q1860 |
P921 | main subject | colorectal cancer | Q188874 |
colorectal carcinoma | Q25493920 | ||
P304 | page(s) | 123 | |
P577 | publication date | 2006-05-08 | |
P1433 | published in | BMC Cancer | Q326300 |
P1476 | title | HER 2/neu protein expression in colorectal cancer | |
P478 | volume | 6 |
Q41835781 | (18)F-FDG PET/CT of advanced gastric carcinoma and association of HER2 expression with standardized uptake value |
Q44885327 | Are biopsy specimens predictive of HER2 status in gastric cancer patients? |
Q38819670 | Cardiotoxicity associated with targeted cancer therapies |
Q47164059 | Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy? |
Q38827897 | Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory |
Q36548702 | Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition |
Q33943812 | Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas |
Q53134672 | Clinicopathological and prognostic significance of HER2 overexpression in gastric cancer: a meta-analysis of the literature. |
Q91865170 | Clinicopathological features and Borrmann classification associated with HER2-positive in primary gastric cancer |
Q33913610 | Comparison of HER2 expression between primary colorectal cancer and their corresponding metastases |
Q26801167 | Correlation of human epidermal growth factor receptor protein expression and colorectal cancer |
Q38087507 | Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer. |
Q39686854 | Early response to ErbB2 over-expression in polarized Caco-2 cells involves partial segregation from ErbB3 by relocalization to the apical surface and initiation of survival signaling |
Q47950050 | ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery. |
Q53091400 | Expression analysis of heat shock protein 90 (HSP90) and Her2 in colon carcinoma. |
Q54501568 | Expression and association of HER2 with prognosis in early-stage (T1-T2N0M0) non-small cell lung cancer. |
Q33626875 | Frequency of HER2/neu overexpression in adenocarcinoma of the gastrointestinal system |
Q37109905 | Genomic markers of panitumumab resistance including ERBB2/ HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC). |
Q37708897 | HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives |
Q28078111 | HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists |
Q43825401 | HER2 and immunotherapy using monoclonal antibodies in colorectal cancer. |
Q38314355 | HER2 assessment by silver in situ hybridization: where are we now? |
Q38364900 | HER2 expression status in diverse cancers: review of results from 37,992 patients |
Q50964844 | HER2 protein expression and HER2 gene amplification are infrequent in small intestinal carcinomas. |
Q34499615 | HER2/neu testing in primary colorectal carcinoma |
Q37824265 | Her-2/neu testing and therapy in gastroesophageal adenocarcinoma |
Q31059013 | Integration of DNA copy number alterations and transcriptional expression analysis in human gastric cancer. |
Q30856729 | Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? |
Q39861972 | KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. |
Q90279899 | KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer - practical implications for the clinician |
Q86876904 | Over-expression of Her-2 in colorectal cancer tissue, but not in serum, constitutes an independent worse prognostic factor |
Q38653309 | Pertuzumab in gastrointestinal cancer |
Q53128686 | Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. |
Q38116869 | RAS signaling pathways, mutations and their role in colorectal cancer |
Q38199128 | Recent advances and future trends in the targeted therapy of metastatic gastric cancer |
Q64116155 | Significance of HER2 protein expression and gene amplification in colorectal adenocarcinomas |
Q34585338 | Significance of human epidermal growth factor receptor 2 expression in colorectal cancer |
Q91291948 | Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients |
Q37725990 | Targeted immunotherapy for colorectal cancer: monoclonal antibodies and immunotoxins |
Q54962247 | Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. |
Q36034067 | The clinical significance of HER2 protein amplification/expression in urinary bladder lesion |
Q33764191 | The validation of a novel method combining both HER2 immunohistochemistry and HER2 dual-colour silver in situ hybridization on one slide for gastric carcinoma testing |
Q33618553 | Tumor suppressor role of miR-3622b-5p in ERBB2-positive cancer |